Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Mustang Bio, Inc.

Mustang Bio, Inc. (“Mustang”) is a clinical-stage bio-pharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang has partnered with top medical institutions to advance the development of CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID.

California Institute for Regenerative Medicine

California Institute of Regenerative Medicine (CIRM)

National Institutes of Health

Runway Growth Capital

Horizon Technology Finance

Mustang Bio

Mustang Bio announces its expansion into #autoimmunediseases with MB-106, a CD20-targeted, 3rd-generation autologous CAR T-cell therapy. A Phase 1 trial is expected to initiate in the fourth quarter of this year to demonstrate clinical proof-of-concept. $MBIO Learn more here: https://bit.ly/4azqUGS

Mustang Bio reports full-year 2023 financial results and recent corporate highlights. $MBIO Read more here: https://bit.ly/3Vdj7Kk

Phase 1 clinical data were published in @NatureMedicine that demonstrated the promising safety and clinical activity of Mustang Bio’s MB-101 (IL13Ra2-targeted CAR T-cells) for the treatment of patients with recurrent and refractory malignant glioma, including #glioblastoma. $MBIO Learn more here:  https://bit.ly/3TeNAVQ


#DYK one out every 10 Americans is living with a rare disease? This #RareDiseaseDay, learn more about Mustang's pipeline and its treatments for rare diseases. https://bit.ly/3Ij0flf #XSCID #BubbleBoyDisease #WaldenstromMacroglobulinemia #GBM $MBIO 


#DYK Waldenstrom Macroglobulinemia (WM) is a rare #bloodcancer that originates from malignant B-cells and there is no FDA-approved therapy or standard of care in the third-line setting? There are about 1,400 new patients per year in the U.S. who are diagnosed with the disease. 
 
This #RareDiseaseDay, learn more about #WM and Mustang Bio’s ongoing MB-106 Phase 1/2 trial here: https://bit.ly/49Ku9KW #CD20-targetedCAR T-cell #WaldenstromMacroglobulinemia $MBIO 

NASDAQ:MBIO

Mustang Bio

Last Close

0.35

26/07 16:49

Market Cap

15.08M

Beta: 1.86

Volume Today

803.25K

Avg: 49.10K

PE Ratio

−0.16

PFCF: −0.23

People Not Available